• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

WARFARIN Drug Record

  • Summary
  • Interactions
  • Claims
  • WARFARIN chembl:CHEMBL1464 Approved

    Alternate Names:

    WARFARIN
    NSC-59813
    PANWARFIN
    4-HYDROXY-3-(3-OXO-1-PHENYLBUTYL)COUMARIN
    MAREVAN®
    ZOOCOUMARIN
    COUMAFENE
    COUMADIN®
    rxcui:11289
    chembl:CHEMBL1464
    pubchem.compound:54678486
    chemidplus:81-81-2
    drugbank:00682

    Drug Info:

    Year of Approval approved before 1982
    Drug Class anticoagulants
    FDA Approval Approved before 1982
    Drug Class small molecule
    Drug Indications Anticoagulants
    (4 More Sources)

    Publications:

    Luo Z et al., 2017, Identification of novel variants associated with warfarin stable dosage by use of a two-stage extreme phenotype strategy., J Thromb Haemost
    Bhatt DK et al., 2019, Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver., Clin Pharmacol Ther
    An SH et al., 2015, Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves., Cardiovasc Ther
    Osman et al., 2007, Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype., Blood Coagul. Fibrinolysis
    Zhu et al., 2007, Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes., Clin. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Yin et al., 2007, Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives., Thromb. Res.
    Gebauer, 2007, Synthesis and structure-activity relationships of novel warfarin derivatives., Bioorg. Med. Chem.
    Limdi et al., 2008, Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin., Clin. Pharmacol. Ther.
    Bader L et al., 2020, The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population., Pharmacogenomics J
    de Oliveira Magalhães Mourão A et al., 2020, Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects., Pharmacogenomics J
    Nakagita K et al., 2018, Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD)., Eur J Clin Pharmacol
    Serna MJ et al., 2018, Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation., Eur J Clin Invest
    Bryk AH et al., 2018, Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms., Vascul Pharmacol
    Zambon CF et al., 2018, Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial., Eur J Clin Pharmacol
    Shahabi P et al., 2019, Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort., Pharmacogenomics J
    Chung JE et al., 2018, Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses., Gene
    Vandell AG et al., 2017, Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism., Heart
    Tang XY et al., 2017, The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement., J Clin Pharm Ther
    Ferrari M et al., 2017, Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes., Eur J Clin Pharmacol
    Lee KE et al., 2017, Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves., Int J Cardiol
    Gaikwad T et al., 2018, Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients., Clin Appl Thromb Hemost
    Misasi S et al., 2016, VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients., Medicine (Baltimore)
    Pourgholi L et al., 2016, Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR)., Toxicol Appl Pharmacol
    Eriksson N et al., 2016, Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy., Pharmacogenomics
    Wakamiya T et al., 2016, Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients., Mol Diagn Ther
    Shahabi P et al., 2016, An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance., Thromb Haemost
    Sridharan K et al., 2016, Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study., Curr Clin Pharmacol
    Mandic D et al., 2015, VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy., Int J Clin Pharmacol Ther
    Zhang J et al., 2015, The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis., Thromb Res
    Chung JE et al., 2015, Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves., Eur J Clin Pharmacol
    Sermsathanasawadi N et al., 2015, The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis., J Med Assoc Thai
    Šupe S et al., 2015, Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke., Arch Med Res
    Mega JL et al., 2015, Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial., Lancet
    Li S et al., 2015, Warfarin dosage response related pharmacogenetics in Chinese population., PLoS One
    Kawai VK et al., 2014, Genotype and risk of major bleeding during warfarin treatment., Pharmacogenomics
    Krishna Kumar D et al., 2015, An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population., Eur J Clin Pharmacol
    de Oliveira Almeida VC et al., 2014, Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study., Mol Diagn Ther
    Valentín II et al., 2014, Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans., P R Health Sci J
    Pavani A et al., 2014, Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches., Pharmacogenomics
    Wypasek E et al., 2014, Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms., Thromb Res
    Jeong E et al., 2015, Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves., Pharmacogenomics J
    Hawcutt DB et al., 2014, Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects., Pharmacogenomics J
    Jiménez-Varo E et al., 2014, Pharmacogenetics role in the safety of acenocoumarol therapy., Thromb Haemost
    Zhao L et al., 2014, Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement., PLoS One
    Shaw K et al., 2014, VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children., Pediatr Blood Cancer
    Hamberg AK et al., 2014, Characterizing variability in warfarin dose requirements in children using modelling and simulation., Br J Clin Pharmacol
    Kadian-Dodov DL et al., 2013, Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects., Vasc Med
    Krishna Kumar D et al., 2014, Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population., Eur J Clin Pharmacol
    Tan SL et al., 2013, Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement., Eur J Clin Pharmacol
    Yang J et al., 2013, Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis., Int J Cardiol
    Tomek A et al., 2013, The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes., Cardiology
    Gaikwad T et al., 2013, Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population., Eur J Pharmacol
    Brehm K et al., 2013, Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism., Eur J Cardiothorac Surg
    Biss TT et al., 2013, The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children., J Thromb Haemost
    Wang LS et al., 2013, Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage., Eur J Clin Pharmacol
    Nguyen N et al., 2013, Genetic and clinical determinants influencing warfarin dosing in children with heart disease., Pediatr Cardiol
    Skov J et al., 2013, The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment., Thromb Res
    Ma C et al., 2012, Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin., Int J Hematol
    Özer M et al., 2013, Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population., Basic Clin Pharmacol Toxicol
    Santos PC et al., 2013, CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation., Eur J Clin Pharmacol
    Pathare A et al., 2012, Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients., J Hum Genet
    Pavani A et al., 2012, Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population., Pharmacogenomics
    Maddison J et al., 2013, The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype., Br J Clin Pharmacol
    Giansante C et al., 2012, Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up., J Thromb Thrombolysis
    Lund K et al., 2012, Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates., Br J Haematol
    Lee KE et al., 2012, Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves., Ther Drug Monit
    Wei M et al., 2012, A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation., Thromb Haemost
    Liang R et al., 2012, Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients., J Thromb Thrombolysis
    Cini M et al., 2012, A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms., Eur J Clin Pharmacol
    Zhang W et al., 2012, Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism., Pharmacogenomics
    Moon HW et al., 2011, The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease., Ann Clin Lab Sci
    Gao L et al., 2011, Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A., Chin Med J (Engl)
    Biss TT et al., 2012, VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children., Blood
    Cho HJ et al., 2011, Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation., Clin Ther
    Johnson JA et al., 2011, Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing., Clin Pharmacol Ther
    Mitchell C et al., 2011, Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population., Pharmacogenomics
    Chan SL et al., 2012, Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia., Pharmacogenomics J
    Choi JR et al., 2011, Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients., J Hum Genet
    Zhong SL et al., 2011, The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement., Eur J Clin Pharmacol
    Kato Y et al., 2011, Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients., Drug Metab Pharmacokinet
    Cavallari LH et al., 2011, Pharmacogenomics of warfarin dose requirements in Hispanics., Blood Cells Mol Dis
    Yang J et al., 2011, Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation., Int J Clin Pharmacol Ther
    Zambon CF et al., 2011, VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study., Pharmacogenomics
    Esmerian MO et al., 2011, Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people., J Clin Pharmacol
    Gan GG et al., 2011, Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations., Ann Hematol
    Nowak-Göttl U et al., 2010, In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes., Blood
    Cha PC et al., 2010, Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese., Hum Mol Genet
    Orsi FA et al., 2010, VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy., Thromb Res
    You JH et al., 2011, Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients., J Thromb Thrombolysis
    Wells PS et al., 2010, A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism., Thromb Res
    Hamberg AK et al., 2010, A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age., Clin Pharmacol Ther
    McMillin GA et al., 2010, Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study., Ther Drug Monit
    Ozer N et al., 2010, The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population., Heart Vessels
    Limdi NA et al., 2010, Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups., Blood
    Cavallari LH et al., 2010, Genetic and clinical predictors of warfarin dose requirements in African Americans., Clin Pharmacol Ther
    Stepien E et al., 2009, A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists., J Appl Genet
    Ferder NS et al., 2010, Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy., J Thromb Haemost
    Pautas E et al., 2010, Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients., Clin Pharmacol Ther
    Sandanaraj E et al., 2009, VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients., Drug Metab Pharmacokinet
    Ohno M et al., 2009, Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients., Eur J Clin Pharmacol
    Fuchshuber-Moraes M et al., 2009, Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin., Eur J Clin Pharmacol
    Limdi NA et al., 2009, Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy., Blood Cells Mol Dis
    Huang SW et al., 2009, Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients., Pharmacogenet Genomics
    Yoshizawa M et al., 2009, Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients., Thromb Res
    Kim HS et al., 2009, Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement., Pharmacogenet Genomics
    Montes R et al., 2008, The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients., Br J Haematol
    Limdi NA et al., 2008, Warfarin pharmacogenetics., Pharmacotherapy
    Stehle S et al., 2008, Pharmacogenetics of oral anticoagulants: a basis for dose individualization., Clin Pharmacokinet
    Meckley LM et al., 2008, An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients., Thromb Haemost
    Wadelius M et al., 2009, The largest prospective warfarin-treated cohort supports genetic forecasting., Blood
    Oner Ozgon G et al., 2008, VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients., Eur J Clin Pharmacol
    Limdi NA et al., 2008, Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans., Pharmacogenomics
    Nakai K et al., 2007, Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients., Pharmacogenomics
    D'Andrea G et al., 2008, Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors., Blood Rev
    Michaud V et al., 2008, Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients., Clin Pharmacol Ther
    Anderson JL et al., 2007, Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation., Circulation
    Caldwell MD et al., 2007, Evaluation of genetic factors for warfarin dose prediction., Clin Med Res
    Cho HJ et al., 2007, Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients., Pharmacogenomics
    Schelleman H et al., 2007, Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians., Clin Pharmacol Ther
    Loebstein R et al., 2007, A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance., Blood
    Kosaki K et al., 2006, 1173C>T polymorphism in VKORC1 modulates the required warfarin dose., Pediatr Cardiol
    Shikata E et al., 2006, Multiple gene polymorphisms and warfarin sensitivity., Eur J Clin Pharmacol
    Li T et al., 2006, Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation., J Med Genet
    Margaglione M et al., 2000, Genetic modulation of oral anticoagulation with warfarin., Thromb Haemost
    Cain D et al., 1998, Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver., Thromb Haemost
    Gage BF et al., 2008, Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues., J Thromb Thrombolysis
    Kimura R et al., 2006, Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population., Int J Hematol
    Gage BF, 2006, Pharmacogenetics-based coumarin therapy., Hematology Am Soc Hematol Educ Program
    Lal et al., 2006, Pharmacogenetics of target genes across the warfarin pharmacological pathway., Clin Pharmacokinet
    Carlquist JF et al., 2006, Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study., J Thromb Thrombolysis
    Kimura R et al., 2007, Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients., Thromb Res
    Sconce EA et al., 2006, Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen., Eur J Haematol
    Tham LS et al., 2006, A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9., Clin Pharmacol Ther
    Wadelius M et al., 2007, Pharmacogenetics of warfarin: current status and future challenges., Pharmacogenomics J
    Rettie AE et al., 2006, The pharmocogenomics of warfarin: closing in on personalized medicine., Mol Interv
    Obayashi K et al., 2006, VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients., Clin Pharmacol Ther
    Kamali F, 2006, Genetic influences on the response to warfarin., Curr Opin Hematol
    Sconce EA et al., 2006, APOE genotype makes a small contribution to warfarin dose requirements., Pharmacogenet Genomics
    Schalekamp et al., 2006, VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation., Clin. Pharmacol. Ther.
    Schwarz UI et al., 2006, Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants., Clin Pharmacol Ther
    Herman D et al., 2006, The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement., Thromb Haemost
    Montes et al., 2006, The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients., Br. J. Haematol.
    Aquilante CL et al., 2006, Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements., Clin Pharmacol Ther
    Vecsler M et al., 2006, Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin., Thromb Haemost
    Mushiroda T et al., 2006, Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients., J Hum Genet
    Geisen C et al., 2005, VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation., Thromb Haemost
    Veenstra DL et al., 2005, Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population., Pharmacogenet Genomics
    Sconce EA et al., 2005, The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen., Blood
    Lee CH et al., 2005, Venous thromboembolism: diagnosis and management of pulmonary embolism., Med J Aust
    Rieder MJ et al., 2005, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose., N Engl J Med
    Yuan HY et al., 2005, A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity., Hum Mol Genet
    Wadelius M et al., 2005, Common VKORC1 and GGCX polymorphisms associated with warfarin dose., Pharmacogenomics J
    Ho WK et al., 2005, Venous thromboembolism: diagnosis and management of deep venous thrombosis., Med J Aust
    Bodin et al., 2005, Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity., Blood
    Nutescu EA, 2004, Emerging options in the treatment of venous thromboembolism., Am J Health Syst Pharm
    D'Andrea G et al., 2005, A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin., Blood
    Li et al., 2004, Identification of the gene for vitamin K epoxide reductase., Nature
    Rost S et al., 2004, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2., Nature
    Wadelius M et al., 2004, Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors., Pharmacogenomics J
    Takahashi H et al., 2003, Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin., Pharmacogenomics J
    Higashi MK et al., 2002, Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy., JAMA
    Wienkers LC et al., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19., Drug Metab Dispos
    Zhang Z et al., 1995, Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe., Drug Metab Dispos
    Lilja JJ et al., 2007, Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4., Clin Pharmacol Ther
    Zhang JE et al., 2017, Effect of Genetic Variability in the <i>CYP4F2</i>, <i>CYP4F11</i>, and <i>CYP4F12</i> Genes on Liver mRNA Levels and Warfarin Response., Front Pharmacol
    Moon JY et al., 2015, Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses., Pharmacogenet Genomics
    Byrne et al., 2004, Warfarin skin necrosis associated with protein S deficiency and a mutation in the methylenetetrahydrofolate reductase gene., Clin. Exp. Dermatol.
    Kudo et al., 1998, Evidence for modulation of osteocalcin containing gamma-carboxyglutamic acid residues synthesis by insulin-like growth factor-I and vitamin K2 in human osteosarcoma cell line MG-63., Eur. J. Endocrinol.
    Tavares LC et al., 2018, Association Between <i>ABCB1</i> Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients., Front Pharmacol
    Thorarensen A et al., 2007, Human serum albumin binding assay based on displacement of a non selective fluorescent inhibitor., Bioorg Med Chem Lett
    An SH et al., 2014, Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves., J Clin Pharm Ther
    Rettie et al., 1985, Stereoselective and regioselective hydroxylation of warfarin and selective O-dealkylation of phenoxazone ethers in human placenta., Biochem. Biophys. Res. Commun.
    Cavallari LH et al., 2011, Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients., Pharmacotherapy
    Ngui JS et al., 2001, In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarin., Drug Metab Dispos
    Nagai et al., 2005, Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy., Kidney Int.
    Lip et al., 1995, Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment., Br Heart J
    Siguret et al., 2004, [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients]., Rev Med Interne
    Zhang H et al., 2016, Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation., Gene
    Chang M et al., 2015, CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy., Eur J Clin Pharmacol
    Liang Y et al., 2013, Association of genetic polymorphisms with warfarin dose requirements in Chinese patients., Genet Test Mol Biomarkers
    Lane S et al., 2012, The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors., Br J Clin Pharmacol
    Jorgensen AL et al., 2009, Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study., Pharmacogenet Genomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
  • WARFARIN   VKORC1

    Interaction Score: 28.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17413769 17510308 11752352 17161452 17275317 17653141 31653973 31395958 29781049 29577257 29432897 29396738 29298995 29054760 28689179 28429387 28382498 28262345 28049362 28033245 27581200 27488176 27262824 27121899 26777610 26445138 26433837 26257249 26223945 26219158 25989350 25769357 25594941 25521356 25519826 25312789 25244877 25084205 25042728 25026456 25001883 24919870 24728385 24474498 24330000 24029542 24019055 23949431 23932037 23774101 23602689 23423913 23279643 23208322 23183958 23159229 23104259 23061746 22990331 22854539 22676192 22616655 22592842 22571356 22549502 22534826 22528326 22349464 22248286 22075505 22040439 22010099 21981797 21900891 21635147 21383771 21326313 21318593 21273734 21185752 21176721 21174619 21148049 21110192 20833980 20833655 20615525 20585834 20421126 20410877 20386359 20339978 20203262 20072124 19875892 19874474 19794411 19745563 19582440 19387626 19297219 19177029 19135231 19077919 18950464 18752379 18698879 18690342 18574025 18542936 18466099 18240904 18234403 18030307 17989110 17456829 17391071 17329985 17110455 17031720 16821005 16611750 11127854 9684798 17906972 17189218 17124101 17112295 17111199 17049586 17042764 17015052 16983400 16960144 16890578 16888441 16847429 16815313 16815312 16676068 16611310 16580898 16493479 16432637 16270629 16141794 15947090 15938684 15930419 15888487 15883587 15865594 15790782 15597574 15358623 14765195 14765194 14676821 12931134 11926893


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD FDA

  • WARFARIN   NEDD4

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27488176


    Sources:
    PharmGKB

  • WARFARIN   VKORC1L1

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    29054760


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • WARFARIN   DDHD1

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27488176


    Sources:
    PharmGKB

  • WARFARIN   CYP4F11

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28620303


    Sources:
    PharmGKB

  • WARFARIN   ASPH

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27488176


    Sources:
    PharmGKB

  • WARFARIN   STX1B

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27740732


    Sources:
    PharmGKB

  • WARFARIN   GAS6

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16014032


    Sources:
    NCI

  • WARFARIN   PRSS53

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • WARFARIN   GATA4

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29298995 25026456


    Sources:
    PharmGKB

  • WARFARIN   STX4

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • WARFARIN   DNMT3A

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27740732


    Sources:
    PharmGKB

  • WARFARIN   THBD

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24602049


    Sources:
    PharmGKB

  • WARFARIN   FPGS

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • WARFARIN   PROS1

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • WARFARIN   NQO1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27740732 27581200 26257249 21923605


    Sources:
    PharmGKB

  • WARFARIN   NR1I3

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29298995 25356900


    Sources:
    PharmGKB

  • WARFARIN   CYP3A7

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3977899


    Sources:
    NCI

  • WARFARIN   APOE

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29432897 21923605


    Sources:
    PharmGKB

  • WARFARIN   CYP1A1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8689941 27740732


    Sources:
    PharmGKB

  • WARFARIN   VWF

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7626351


    Sources:
    NCI

  • WARFARIN   HNF4A

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25356900


    Sources:
    PharmGKB

  • WARFARIN   PROC

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • WARFARIN   ALB

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17560104


    Sources:
    DTC

  • WARFARIN   BGLAP

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9578515


    Sources:
    NCI

  • WARFARIN   UGT1A1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29737521 26223945


    Sources:
    PharmGKB

  • WARFARIN   MTHFR

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14723717


    Sources:
    NCI

  • WARFARIN   APOB

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • WARFARIN   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29875668 29432897 25312789 22248286


    Sources:
    PharmGKB

  • WARFARIN   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • WARFARIN   CYP2C19

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8723744 27356304 25652102 23941071 21692828 19752777 18574025


    Sources:
    PharmGKB

  • WARFARIN   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15050794


    Sources:
    NCI FDA

  • WARFARIN   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8723744 8689941 17392729


    Sources:
    PharmGKB

  • WARFARIN   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29298995


    Sources:
    PharmGKB

  • WARFARIN   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • WARFARIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11353757


    Sources:
    PharmGKB

  • TdgClinicalTrial: WARFARIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anticoagulants
    Drug Class small molecule
    FDA Approval Approved before 1982

    Publications:

  • TEND: WARFARIN

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class anticoagulants
    Year of Approval approved before 1982

    Publications:

  • NCI: WARFARIN

    • Version: 14-September-2017

    Alternate Names:
    C945 NCI drug code

    Drug Info:

    Publications:
    Nagai et al., 2005, Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy., Kidney Int.
    Siguret et al., 2004, [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients]., Rev Med Interne
    Rettie et al., 1985, Stereoselective and regioselective hydroxylation of warfarin and selective O-dealkylation of phenoxazone ethers in human placenta., Biochem. Biophys. Res. Commun.

  • DTC: WARFARIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1464 ChEMBL Drug ID

    Drug Info:

    Publications:
    Thorarensen A et al., 2007, Human serum albumin binding assay based on displacement of a non selective fluorescent inhibitor., Bioorg Med Chem Lett

  • PharmGKB: warfarin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Luo Z et al., 2017, Identification of novel variants associated with warfarin stable dosage by use of a two-stage extreme phenotype strategy., J Thromb Haemost
    Wienkers LC et al., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19., Drug Metab Dispos
    Lilja JJ et al., 2007, Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4., Clin Pharmacol Ther

  • TTD: Warfarin

    • Version: 2020.06.01

    Alternate Names:
    D0E3OF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1464

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Warfarin

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21